02.12.2014
- In a late-stage study involving 970 people with primary-progressive multiple sclerosis (PPMS), the Novartis drug Gilenya (fingolimod) failed to show any significant advantages over...
18.07.2013
- Novartis raised its full-year outlook on Wednesday after generic competition to its best-selling blood pressure pill was delayed, granting the Swiss drugmaker a temporary reprieve...
19.07.2012
- Swiss drugmaker Novartis posted a smaller than expected fall in second-quarter core earnings and said tight cost control and strong sales of new drugs would help it cope with a...
21.01.2011
- European regulators dealt Merck KGaA another blow by sticking with their recommendation against what once was the group's biggest pipeline hope, multiple sclerosis (MS) pill...
21.01.2011
- European regulators dealt Merck KGaA another blow by sticking with their recommendation against what once was the group's biggest pipeline hope, multiple sclerosis (MS) pill...
21.12.2010
- Genzyme argued that its experimental multiple sclerosis treatment will garner far higher sales than Sanofi-Aventis is projecting, as it aims to wrest a significantly higher bid...
